Tadal 20 Uses

sponsored
How do you administer this medicine?

What is Tadal 20?

Tadal 20 is used to treat men who have erectile dysfunction (also called sexual impotence). Tadal 20 belongs to a group of medicines called phosphodiesterase 5 (PDE5) inhibitors. These medicines prevent an enzyme called phosphodiesterase type-5 from working too quickly. The penis is one of the areas where this enzyme works.

Erectile dysfunction is a condition where the penis does not harden and expand when a man is sexually excited, or when he cannot keep an erection. When a man is sexually stimulated, his body's normal response is to increase blood flow to his penis to produce an erection. By controlling the enzyme, Tadal 20 helps to maintain an erection after the penis is stroked by increasing blood flow to the penis. Without physical action to the penis, such as that occurring during sexual intercourse, Tadal 20 will not work to cause an erection.

Tadal 20 is also used to treat men who have signs and symptoms of benign prostatic hyperplasia (BPH). BPH is caused by an enlarged prostate. Men with BPH usually have difficulty urinating, a decreased flow of urination, hesitation at the beginning of urination, and a need to get up at night to urinate. Tadal 20 will make these symptoms less severe and reduce the chance that prostate surgery will be needed. Tadal 20 is also used to treat erectile dysfunction and signs and symptoms of BPH.

Tadal 20 is also used in both men and women to treat the symptoms of pulmonary arterial hypertension. This is high blood pressure that occurs in the main artery that carries blood from the right side of the heart (the ventricle) to the lungs. When the smaller blood vessels in the lungs become more resistant to blood flow, the right ventricle must work harder to pump enough blood through the lungs. Tadal 20 works on the PDE5 enzyme in the lungs to relax the blood vessels. This will increase the supply of blood to the lungs and reduce the workload of the heart.

Tadal 20 is available only with your doctor's prescription..

Tadal 20 indications

infoAn indication is a term used for the list of condition or symptom or illness for which the medicine is prescribed or used by the patient. For example, acetaminophen or paracetamol is used for fever by the patient, or the doctor prescribes it for a headache or body pains. Now fever, headache and body pains are the indications of paracetamol. A patient should be aware of the indications of medications used for common conditions because they can be taken over the counter in the pharmacy meaning without prescription by the Physician.
sponsored

Erectile Dysfunction

Tadal 20 tablets are indicated for the treatment of erectile dysfunction (ED).

Benign Prostatic Hyperplasia

Tadal 20 tablets are indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH).

Erectile Dysfunction and Benign Prostatic Hyperplasia

Tadal 20 tablets are indicated for the treatment of ED and the signs and symptoms of BPH (ED/BPH).

Limitation of Use

If Tadal 20 tablets are used with finasteride to initiate BPH treatment, such use is recommended for up to 26 weeks because the incremental benefit of Tadal 20 tablets decrease from 4 weeks until 26 weeks, and the incremental benefit of Tadal 20 tablets beyond 26 weeks is unknown.

How should I use Tadal 20?

Use Tadal 20 as directed by your doctor. Check the label on the medicine for exact dosing instructions.

  • An extra patient leaflet is available with Tadal 20. Talk to your pharmacist if you have questions about this information.
  • Take Tadal 20 by mouth with or without food.
  • Swallow Tadal 20 whole. Do not break the tablet before swallowing.
  • For use as needed: Take Tadal 20 at least 30 minutes before sexual activity, as directed by your doctor. Tadal 20 may work for up to 36 hours after you take it.
  • For daily use: Take Tadal 20 regularly at about the same time each day.
  • Talk with your doctor if you have questions about how you should take Tadal 20.
  • Check with your doctor before you eat grapefruit or drink grapefruit juice while you are taking Tadal 20.
  • For use as needed: If you miss a dose of Tadal 20 and you still intend to engage in sexual activity, take it as soon as you remember. Continue to take it as directed by your doctor. For daily use: If you miss a dose of Tadal 20, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses within the same day.

Ask your health care provider any questions you may have about how to use Tadal 20.

Uses of Tadal 20 in details

infoThere are specific as well as general uses of a drug or medicine. A medicine can be used to prevent a disease, treat a disease over a period or cure a disease. It can also be used to treat the particular symptom of the disease. The drug use depends on the form the patient takes it. It may be more useful in injection form or sometimes in tablet form. The drug can be used for a single troubling symptom or a life-threatening condition. While some medications can be stopped after few days, some drugs need to be continued for prolonged period to get the benefit from it.
sponsored

Tadal 20 is used to treat high blood pressure in the lungs (pulmonary hypertension). It works by relaxing and widening the blood vessels in your lungs which allows the blood to flow more easily. Decreasing high blood pressure in the lungs allows your heart and lungs to work better and improves your ability to exercise.

OTHER USES: This section contains uses of this drug that are not listed in the approved professional labeling for the drug but that may be prescribed by your health care professional. Use this drug for a condition that is listed in this section only if it has been so prescribed by your health care professional.

Tadal 20 is also available in another brand for treating erectile dysfunction-ED in men. It may also be used to treat the symptoms of an enlarged prostate (benign prostatic hyperplasia-BPH).

How to use Tadal 20

Read the Patient Information Leaflet provided by your pharmacist before you start taking Tadal 20 and each time you get a refill. If you have any questions, ask your doctor or pharmacist.

To treat high blood pressure in the lungs, take this medication by mouth as directed by your doctor, with or without food, usually once daily.

The dosage is based on your medical condition, response to treatment, and other medications you may be taking. Be sure to tell your doctor and pharmacist about all the products you use (including prescription drugs, nonprescription drugs, and herbal products).

Take this medication regularly to get the most benefit from it. To help you remember, take it at the same time each day.

Tell your doctor if your condition does not improve or if it worsens.

Tadal 20 description

sponsored

Tadal 20 is an orally adminstered drug used to treat male erectile dysfunction (impotence). It is marketed worldwide under the brand name Tadal 20. It is a phosphodiesterase 5 (PDE5) inhibitor. Tadal 20's distinguishing pharmacologic feature is its longer half-life (17.5 hours) compared with Viagra and Levitra (4-5 hours). This longer half-life results in a longer duration of action and is, in part, responsible for the Tadal 20 nickname of the "weekend pill." This longer half-life also is the basis of current investigation for Tadal 20's use in pulmonary arterial hypertension as a once-daily therapy. [Wikipedia]

Tadal 20 dosage

Do not split Tadal 20 tablets; entire dose should be taken.

Tadal 20 for Use as Needed for Erectile Dysfunction

  • The recommended starting dose of Tadal 20 for use as needed in most patients is 10 mg, taken prior to anticipated sexual activity.
  • The dose may be increased to 20 mg or decreased to 5 mg, based on individual efficacy and tolerability. The maximum recommended dosing frequency is once per day in most patients.
  • Tadal 20 for use as needed was shown to improve erectile function compared to placebo up to 36 hours following dosing. Therefore, when advising patients on optimal use of Tadal 20, this should be taken into consideration.

Tadal 20 for Once Daily Use for Erectile Dysfunction

  • The recommended starting dose of Tadal 20 for once daily use is 2.5 mg, taken at approximately the same time every day, without regard to timing of sexual activity.
  • The Tadal 20 dose for once daily use may be increased to 5 mg, based on individual efficacy and tolerability.

Tadal 20 for Once Daily Use for Benign Prostatic Hyperplasia

  • The recommended dose of Tadal 20 for once daily use is 5 mg, taken at approximately the same time every day.
  • When therapy for BPH is initiated with Tadal 20 and finasteride, the recommended dose of Tadal 20 for once daily use is 5 mg, taken at approximately the same time every day for up to 26 weeks.

Tadal 20 for Once Daily Use for Erectile Dysfunction and Benign Prostatic Hyperplasia

The recommended dose of Tadal 20 for once daily use is 5 mg, taken at approximately the same time every day, without regard to timing of sexual activity.

Use with Food

Tadal 20 may be taken without regard to food.

Use in Specific Populations

Renal Impairment

Tadal 20 for Use as Needed

  • Creatinine clearance 30 to 50 mL/min: A starting dose of 5 mg not more than once per day is recommended, and the maximum dose is 10 mg not more than once in every 48 hours.
  • Creatinine clearance less than 30 mL/min or on hemodialysis: The maximum dose is 5 mg not more than once in every 72 hours.

Tadal 20 for Once Daily Use

Erectile Dysfunction

  • Creatinine clearance less than 30 mL/min or on hemodialysis: Tadal 20 for once daily use is not recommended.

Benign Prostatic Hyperplasia and Erectile Dysfunction/Benign Prostatic Hyperplasia

  • Creatinine clearance 30 to 50 mL/min: A starting dose of 2.5 mg is recommended. An increase to 5 mg may be considered based on individual response.
  • Creatinine clearance less than 30 mL/min or on hemodialysis: Tadal 20 for once daily use is not recommended.

Hepatic Impairment

Tadal 20 for Use as Needed

  • Mild or moderate (Child Pugh Class A or B): The dose should not exceed 10 mg once per day. The use of Tadal 20 once per day has not been extensively evaluated in patients with hepatic impairment and therefore, caution is advised.
  • Severe (Child Pugh Class C): The use of Tadal 20 is not recommended.

Tadal 20 for Once Daily Use

  • Mild or moderate (Child Pugh Class A or B): Tadal 20 for once daily use has not been extensively evaluated in patients with hepatic impairment. Therefore, caution is advised if Tadal 20 for once daily use is prescribed to these patients.
  • Severe (Child Pugh Class C): The use of Tadal 20 is not recommended.

Concomitant Medications

Nitrates

Concomitant use of nitrates in any form is contraindicated.

Alpha-Blockers

ED — When Tadal 20 is coadministered with an alpha-blocker in patients being treated for ED, patients should be stable on alpha-blocker therapy prior to initiating treatment, and Tadal 20 should be initiated at the lowest recommended dose.

BPH — Tadal 20 is not recommended for use in combination with alpha-blockers for the treatment of BPH.

CYP3A4 Inhibitors

Tadal 20 for Use as Needed — For patients taking concomitant potent inhibitors of CYP3A4, such as ketoconazole or ritonavir, the maximum recommended dose of Tadal 20 is 10 mg, not to exceed once every 72 hours.

Tadal 20 for Once Daily Use — For patients taking concomitant potent inhibitors of CYP3A4, such as ketoconazole or ritonavir, the maximum recommended dose is 2.5 mg.

Tadal 20 interactions

See also:
What other drugs will affect Tadal 20?

sponsored

Potential For Pharmacodynamic Interactions With Tadal 20

Nitrates

Administration of Tadal 20 to patients who are using any form of organic nitrate, is contraindicated. In clinical pharmacology studies, Tadal 20 was shown to potentiate the hypotensive effect of nitrates. In a patient who has taken Tadal 20, where nitrate administration is deemed medically necessary in a life-threatening situation, at least 48 hours should elapse after the last dose of Tadal 20 before nitrate administration is considered. In such circumstances, nitrates should still only be administered under close medical supervision with appropriate hemodynamic monitoring.

Alpha-Blockers

Caution is advised when PDE5 inhibitors are coadministered with alpha-blockers. PDE5 inhibitors, including Tadal 20, and alpha-adrenergic blocking agents are both vasodilators with blood-pressure-lowering effects. When vasodilators are used in combination, an additive effect on blood pressure may be anticipated. Clinical pharmacology studies have been conducted with coadministration of Tadal 20 with doxazosin, tamsulosin or alfuzosin..

Antihypertensives

PDE5 inhibitors, including Tadal 20, are mild systemic vasodilators. Clinical pharmacology studies were conducted to assess the effect of Tadal 20 on the potentiation of the bloodpressure- lowering effects of selected antihypertensive medications (amlodipine, angiotensin II receptor blockers, bendrofluazide, enalapril, and metoprolol). Small reductions in blood pressure occurred following coadministration of Tadal 20 with these agents compared with placebo..

Alcohol

Both alcohol and Tadal 20, a PDE5 inhibitor, act as mild vasodilators. When mild vasodilators are taken in combination, blood-pressure-lowering effects of each individual compound may be increased. Substantial consumption of alcohol (e.g., 5 units or greater) in combination with Tadal 20 can increase the potential for orthostatic signs and symptoms, including increase in heart rate, decrease in standing blood pressure, dizziness, and headache. Tadal 20 did not affect alcohol plasma concentrations and alcohol did not affect Tadal 20 plasma concentrations..

Potential For Other Drugs To Affect Tadal 20

.

Antacids

Simultaneous administration of an antacid (magnesium hydroxide/aluminum hydroxide) and Tadal 20 reduced the apparent rate of absorption of Tadal 20 without altering exposure (AUC) to Tadal 20.

H2 Antagonists (e.g. Nizatidine)

An increase in gastric pH resulting from administration of nizatidine had no significant effect on pharmacokinetics.

Cytochrome P450 Inhibitors

Tadal 20 is a substrate of and predominantly metabolized by CYP3A4. Studies have shown that drugs that inhibit CYP3A4 can increase Tadal 20 exposure.

CYP3A4 (e.g., Ketoconazole)

Ketoconazole (400 mg daily), a selective and potent inhibitor of CYP3A4, increased Tadal 20 20 mg single-dose exposure (AUC) by 312% and Cmax by 22%, relative to the values for Tadal 20 20 mg alone. Ketoconazole (200 mg daily) increased Tadal 20 10-mg singledose exposure (AUC) by 107% and Cmax by 15%, relative to the values for Tadal 20 10 mg alone.

Although specific interactions have not been studied, other CYP3A4 inhibitors, such as erythromycin, itraconazole, and grapefruit juice, would likely increase Tadal 20 exposure.

HIV Protease inhibitor

Ritonavir (500 mg or 600 mg twice daily at steady state), an inhibitor of CYP3A4, CYP2C9, CYP2C19, and CYP2D6, increased Tadal 20 20-mg single-dose exposure (AUC) by 32% with a 30% reduction in Cmax, relative to the values for Tadal 20 20 mg alone. Ritonavir (200 mg twice daily), increased Tadal 20 20-mg single-dose exposure (AUC) by 124% with no change in Cmax, relative to the values for Tadal 20 20 mg alone. Although specific interactions have not been studied, other HIV protease inhibitors would likely increase Tadal 20 exposure.

Cytochrome P450 Inducers

Studies have shown that drugs that induce CYP3A4 can decrease Tadal 20 exposure.

CYP3A4 (e.g., Rifampin)

Tadal 20 side effects

See also:
What are the possible side effects of Tadal 20?

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Tadal 20 was administered to over 9000 men during clinical trials worldwide. In trials of Tadal 20 for once daily use, a total of 1434, 905, and 115 were treated for at least 6 months, 1 year, and 2 years, respectively. For Tadal 20 for use as needed, over 1300 and 1000 subjects were treated for at least 6 months and 1 year, respectively.

Tadal 20 For Use As Needed For ED

In eight primary placebo-controlled clinical studies of 12 weeks duration, mean age was 59 years (range 22 to 88) and the discontinuation rate due to adverse events in patients treated with Tadal 20 10 or 20 mg was 3.1%, compared to 1.4% in placebo treated patients.

When taken as recommended in the placebo-controlled clinical trials, the following adverse reactions were reported for Tadal 20 for use as needed:

Table 1: Treatment-Emergent Adverse Reactions Reported by ≥ 2% of Patients Treated with Tadal 20 (10 or 20 mg) and More Frequent on Drug than Placebo in the Eight Primary Placebo- Controlled Clinical Studies (Including a Study in Patients with Diabetes ) for Tadal 20 for Us e as Needed for ED

Adverse Reaction Placebo

(N=476)

Tadal 20 5 mg

(N=151)

Tadal 20 10 mg

(N=394)

Tadal 20 20 mg

(N=635)

Headache 5% 11% 11% 15%
Dyspepsia 1% 4% 8% 10%
Back pain 3% 3% 5% 6%
Myalgia 1% 1% 4% 3%
Nasal congestion 1% 2% 3% 3%
FlushingThe term flushing includes: facial flushing and flushing

Tadal 20 For Once Daily Use For ED

In three placebo-controlled clinical trials of 12 or 24 weeks duration, mean age was 58 years (range 21 to 82) and the discontinuation rate due to adverse events in patients treated with Tadal 20 was 4.1%, compared to 2.8% in placebo-treated patients.

The following adverse reactions were reported in clinical trials of 12 weeks duration:

Table 2: Treatment-Emergent Adverse Reactions Reported by ≥ 2% of Patients Treated with Tadal 20 for Once Daily Us e (2.5 or 5 mg) and More Frequent on Drug than Placebo in the Three Primary Placebo-Controlled Phase 3 Studies of 12 weeks Treatment Duration (Including a Study in Patients with Diabetes ) for Tadal 20 for Once Daily Us e for ED

Adverse Reaction Placebo

(N=248)

Tadal 20 2.5 mg

(N=196)

Tadal 20 5 mg

(N=304)

Headache 5% 3% 6%
Dyspepsia 2% 4% 5%
Naso pharyngitis 4% 4% 3%
Back pain 1% 3% 3%
Upper respiratory tract infection 1% 3% 3%
Flushing 1% 1% 3%
Myalgia 1% 2% 2%
Cough 0% 4% 2%
Diarrhea 0% 1% 2%
Nasal congestion 0% 2% 2%
Pain in extremity 0% 1% 2%
Urinary tract infection 0% 2% 0%
Gastroesophageal reflux disease 0% 2% 1%
Abdominal pain 0% 2% 1%

The following adverse reactions were reported over 24 weeks treatment duration in one placebo-controlled clinical study:

Table 3: Treatment-Emergent Adverse Reactions Reported by ≥ 2% of Patients Treated with Tadal 20 for Once Daily Us e (2.5 or 5 mg) and More Frequent on Drug than Placebo in One Placebo-Controlled Clinical Study of 24 Weeks Treatment Duration for Tadal 20 for Once Daily Use for ED

Adverse Reaction Placebo

(N=94)

Tadal 20 2.5 mg

(N=96)

Tadal 20 5 mg

(N=97)

Naso pharyngitis 5% 6% 6%
Gastroenteritis 2% 3% 5%
Back pain 3% 5% 2%
Upper respiratory tract infection 0% 3% 4%
Dyspepsia 1% 4% 1%
Gastroesophageal reflux disease 0% 3% 2%
Myalgia 2% 4% 1%
Hypertension 0% 1% 3%
Nasal congestion 0% 0% 4%

Tadal 20 For Once Daily Use For BPH And For ED And BPH

In three placebo-controlled clinical trials of 12 weeks duration, two in patients with BPH and one in patients with ED and BPH, the mean age was 63 years (range 44 to 93) and the discontinuation rate due to adverse events in patients treated with Tadal 20 was 3.6% compared to 1.6% in placebo-treated patients. Adverse reactions leading to discontinuation reported by at least 2 patients treated with Tadal 20 included headache, upper abdominal pain, and myalgia. The following adverse reactions were reported.

Table 4: Treatment-Emergent Adverse Reactions Reported by ≥ 1% of Patients Treated with Tadal 20 for Once Daily Use (5 mg) and More Frequent on Drug than Placebo in Three Placebo- Controlled Clinical Studies of 12 Weeks Treatment Duration, including Two Studies for Tadal 20 for Once Daily Us e for BPH and One Study for ED and BPH

Adverse Reaction Placebo

(N=576)

Tadal 20 5 mg

(N=581)

Headache 2.3% 4.1%
Dyspepsia 0.2% 2.4%
Back pain 1.4% 2.4%
Naso pharyngitis 1.6% 2.1%
Diarrhea 1.0% 1.4%
Pain in extremity 0.0% 1.4%
Myalgia 0.3% 1.2%
Dizziness 0.5% 1.0%

Additional, less frequent adverse reactions ( < 1%) reported in the controlled clinical trials of Tadal 20 for BPH or ED and BPH included: gastroesophageal reflux disease, upper abdominal pain, nausea, vomiting, arthralgia, and muscle spasm.

Back pain or myalgia was reported at incidence rates described in Tables 1 through 4. In Tadal 20 clinical pharmacology trials, back pain or myalgia generally occurred 12 to 24 hours after dosing and typically resolved within 48 hours. The back pain/myalgia associated with Tadal 20 treatment was characterized by diffuse bilateral lower lumbar, gluteal, thigh, or thoracolumbar muscular discomfort and was exacerbated by recumbency. In general, pain was reported as mild or moderate in severity and resolved without medical treatment, but severe back pain was reported with a low frequency ( < 5% of all reports). When medical treatment was necessary, acetaminophen or non-steroidal anti-inflammatory drugs were generally effective; however, in a small percentage of subjects who required treatment, a mild narcotic (e.g., codeine) was used. Overall, approximately 0.5% of all subjects treated with Tadal 20 for on demand use discontinued treatment as a consequence of back pain/myalgia. In the 1-year open label extension study, back pain and myalgia were reported in 5.5% and 1.3% of patients, respectively. Diagnostic testing, including measures for inflammation, muscle injury, or renal damage revealed no evidence of medically significant underlying pathology. Incidence rates for Tadal 20 for once daily use for ED, BPH and BPH/ED are described in Tables 2, 3 and 4. In studies of Tadal 20 for once daily use, adverse reactions of back pain and myalgia were generally mild or moderate with a discontinuation rate of < 1% across all indications.

Across placebo-controlled studies with Tadal 20 for use as needed for ED, diarrhea was reported more frequently in patients 65 years of age and older who were treated with Tadal 20 (2.5% of patients).

Across all studies with any Tadal 20 dose, reports of changes in color vision were rare ( < 0.1% of patients).

The following section identifies additional, less frequent events ( < 2%) reported in controlled clinical trials of Tadal 20 for once daily use or use as needed. A causal relationship of these events to Tadal 20 is uncertain. Excluded from this list are those events that were minor, those with no plausible relation to drug use, and reports too imprecise to be meaningful:

Body as a Whole - asthenia, face edema, fatigue, pain, peripheral edema

Cardiovascular - angina pectoris, chest pain, hypotension, myocardial infarction, postural hypotension, palpitations, syncope, tachycardia

Digestive - abnormal liver function tests, dry mouth, dysphagia, esophagitis, gastritis, GGTP increased, loose stools, nausea, upper abdominal pain, vomiting, gastroesophageal reflux disease, hemorrhoidal hemorrhage, rectal hemorrhage

Musculoskeletal - arthralgia, neck pain

Nervous - dizziness, hypesthesia, insomnia, paresthesia, somnolence, vertigo Renal and Urinary

Tadal 20 contraindications

See also:
What is the most important information I should know about Tadal 20?

5 mg Film-coated Tablet: Hypersensitivity to the active substance or to any of the excipients.

In clinical studies, Tadal 20 was shown to augment the hypotensive effects of nitrates. This is thought to result from the combined effects of nitrates and Tadal 20 on the nitric oxide/cGMP pathway. Therefore, administration of Tadal 20 to patients who are using any form of organic nitrate is contraindicated..

Tadal 20, must not be used in men with cardiac disease for whom sexual activity is inadvisable. Physicians should consider the potential cardiac risk of sexual activity in patients with pre-existing cardiovascular disease.

20 mg Film-coated Tablet: Nitrates and Tadal 20 must not be used concomitantly. Co-administration of Tadal 20 with nitric oxide donors, organic nitrates or organic nitrites in any form either regularly or intermittently is contraindicated. Drugs which must not be used concomitantly include, but are not limited to, glyceryl trinitrate (injection, tablets, sprays or patches), isosorbide salts, sodium nitroprusside, amyl nitrite, nicorandil or organic nitrates in any form. In clinical studies, Tadal 20 was shown to potentiate the hypotensive effects of both acute and chronic nitrate administration. This is thought to result from the combined effects of nitrates and Tadal 20 on the nitric oxide/cGMP pathway.

Based on the results of a clinical study in which 150 subjects receiving daily doses of Tadal 20 20 mg for 7 days and 0.4 mg sublingual nitroglycerin at various times, this interaction lasted for more than 24 hours and was no longer detectable when 48 hours had elapsed after the last Tadal 20 dose. Thus, in a patient prescribed Tadal 20, where nitrate administration is deemed medically necessary in a life-threatening situation, at least 48 hours should have elapsed after the last dose of Tadal 20 before nitrate administration is considered. In such circumstances, nitrates should only be administered under close medical supervision with appropriate haemodynamic monitoring.

5 mg and 20 mg Film-coated Tablet: The following groups of patients with cardiovascular disease were not included in clinical trials and the use of Tadal 20 is therefore contraindicated: Patients with myocardial infarction within the last 90 days; patients with unstable angina or angina occurring during sexual intercourse; patients with New York Heart Association Class 2 or greater heart failure in the last 6 months; patients with uncontrolled arrhythmias, hypotension (<90/50 mm Hg), or uncontrolled hypertension; patients with a stroke within the last 6 months.

Tadal 20 is contraindicated in patients who have loss of vision in one eye because of non-arteritic anterior ischaemic optic neuropathy (NAION), regardless of whether this episode was in connection or not with previous PDE5 inhibitor exposure.

Tadal 20 should not be used in patients with a known hypersensitivity to Tadal 20 or to any ingredient of the tablet.



Active ingredient matches for Tadal 20:

Tadalafil in Argentina.


List of Tadal 20 substitutes (brand and generic names)

Sort by popularity
Unit description / dosage (Manufacturer)Price, USD
Cialis 30 5 mg tablet Box$ 140.77
Cialis 10 mg tablet$ 20.92
Cialis 20 mg tablet$ 20.92
Cialis 2.5 mg tablet$ 4.76
Cialis 5 mg tablet$ 4.76
Brand Tadalafil 10mg - 8 Tablets$ 74.99
Brand Tadalafil 10mg - 12 Tablets$ 104.95
Brand Tadalafil 10mg - 16 Tablets$ 134.95
Generic Tadalafil 10 mg - 90 Tablets$ 119.95
Generic Tadalafil 10 mg - 180 Tablets$ 169.95
Generic Tadalafil 20 mg - 90 Tablets$ 124.95
Generic Tadalafil 20 mg - 180 Tablets$ 174.95
Brand Tadalafil 20 mg - 8 Tablets$ 79.95
Brand Tadalafil 20 mg - 12 Tablets$ 109.95
Brand Tadalafil 20 mg - 16 Tablets$ 142.95
Generic Tadalafil 10 mg - 10 Tablets$ 36.95
Generic Tadalafil 10 mg - 30 Tablets$ 69.95
Generic Tadalafil 10 mg - 60 Tablets$ 99.95
Generic Tadalafil 20 mg - 10 Tablets$ 34.95
Generic Tadalafil 20 mg - 30 Tablets$ 74.95
Generic Tadalafil 20 mg - 60 Tablets$ 109.95
Tadalafil tablet 5 mg (Sanis Health Inc (Canada))
Tadalafil tablet 10 mg (Sanis Health Inc (Canada))
Tadalafil tablet 20 mg (Sanis Health Inc (Canada))
TADALAFIL 20MG TABLET 1 strip / 4 tablets each (Jan Aushadhi)$ 0.12

References

  1. DailyMed. "TADALAFIL: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
  2. PubChem. "Tadalafil". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
  3. DrugBank. "Tadalafil". http://www.drugbank.ca/drugs/DB00820 (accessed September 17, 2018).

Reviews

The results of a survey conducted on ndrugs.com for Tadal 20 are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Tadal 20. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

User reports

Consumer reported useful

No survey data has been collected yet


Consumer reported price estimates

No survey data has been collected yet


Consumer reported time for results

No survey data has been collected yet


Consumer reported age

No survey data has been collected yet


Consumer reviews


There are no reviews yet. Be the first to write one!


Your name: 
Email: 
Spam protection:  < Type 26 here

Information checked by Dr. Sachin Kumar, MD Pharmacology

| Privacy Policy
This site does not supply any medicines. It contains prices for information purposes only.
© 2003 - 2020 ndrugs.com All Rights Reserved